Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Socio-demographic and clinical characteristics of the study population (n = 300). Variable | N (%)/Median | 95% Confidence Interval/IQR: Serum vitamin D | 71.5 | 55.0 to 92.5
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Observational study.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Methods: We conducted a single-center cross-sectional observational study at Saqr Hospital, Ras al Khaimah, UAE, between October 2024 and May 2025, enrolling 300 adults with clinically diagnosed osteoporosis and/or a bone mineral density T-score ≤ −2.5.
Source: Abstract.
Participants were included in the study if they were 18 years of age or older, met the criteria for osteoporosis based on clinical evaluation and/or the results from a bone mineral density test, received osteoporosis treatment, and agreed to participate.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Real-World Osteoporosis Pharmacotherapy in the UAE: Prescribing Trends, Adherence, and Patient Beliefs
Observational study · Healthcare · 2026
Original publication title
Real-World Osteoporosis Pharmacotherapy in the UAE: Prescribing Trends, Adherence, and Patient Beliefs
© 2026 by the authors.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Osteoporosis is a chronic bone disease characterized by reduced bone mass and structural deterioration, increasing fracture risk and affecting patients’ quality of life (QoL). Pharmacological treatments are essential in managing osteoporosis; however, suboptimal prescribing patterns and poor medication adherence can limit therapeutic outcomes. This study primarily aimed to assess medication adherence among patients with osteoporosis using the MMAS-8, as well as prescribing patterns and patient beliefs.
Source: Background:Abstract: Results
The median age was 70 years (IQR 63 to 76), 89.0% of participants were female, and 32.0% had a prior fracture history. Denosumab was the most frequently prescribed anti-osteoporotic therapy (59.0%), followed by romosozumab (30.7%), whereas bisphosphonates and parathyroid hormone analogues were infrequently used (2.7% and 4.7%, respectively). Prescribed dosing closely aligned with WHO standards for all evaluated agents. Overall, 40.7% of patients were classified as adherent and 59.3% as non-adherent. Adherence was not significantly associated with age, gender, nationality, fracture history, polypharmacy, or most comorbidities. In contrast, medication beliefs demonstrated a strong relationship with adherence. In multivariable Firth regression, stronger medication concerns were independently associated with lower odds of adherence (adjusted OR 0.033, 95% CI 0.003 to 0.355; p = 0.0049), while having more than two comorbidities was also associated with reduced adherence (adjusted OR 0.076, 95% CI 0.008 to 0.688; p = 0.022).
Source: Results:Abstract: Conclusions
In this UAE real-world cohort, osteoporosis pharmacotherapy was dominated by injectable biologic agents and was prescribed in close agreement with standard dosing recommendations. However, medication adherence remained suboptimal. Patient beliefs, particularly treatment-related concerns, emerged as a more important determinant of adherence than demographic or most clinical characteristics. These findings highlight the need for belief-sensitive, patient-centered adherence interventions alongside optimized pharmacotherapy to improve osteoporosis outcomes in routine practice.
Source: Conclusions:Authors’ abstract
Background:
Osteoporosis is a chronic bone disease characterized by reduced bone mass and structural deterioration, increasing fracture risk and affecting patients’ quality of life (QoL). Pharmacological treatments are essential in managing osteoporosis; however, suboptimal prescribing patterns and poor medication adherence can limit therapeutic outcomes. This study primarily aimed to assess medication adherence among patients with osteoporosis using the MMAS-8, as well as prescribing patterns and patient beliefs.
Methods:
We conducted a single-center cross-sectional observational study at Saqr Hospital, Ras al Khaimah, UAE, between October 2024 and May 2025, enrolling 300 adults with clinically diagnosed osteoporosis and/or a bone mineral density T-score ≤ −2.5. Data were collected through structured interviews and medical-record review. Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8), and beliefs about medicines were measured using the Beliefs about Medicines Questionnaire (BMQ). Prescribing patterns were characterized by drug class, dose, and frequency, and prescribing appropriateness was evaluated using prescribed daily dose/defined daily dose (PDD/DDD) ratios based on WHO ATC/DDD standards. Predictors of adherence were examined using univariate and multivariable Firth penalized logistic regression.
Results:
The median age was 70 years (IQR 63 to 76), 89.0% of participants were female, and 32.0% had a prior fracture history. Denosumab was the most frequently prescribed anti-osteoporotic therapy (59.0%), followed by romosozumab (30.7%), whereas bisphosphonates and parathyroid hormone analogues were infrequently used (2.7% and 4.7%, respectively). Prescribed dosing closely aligned with WHO standards for all evaluated agents. Overall, 40.7% of patients were classified as adherent and 59.3% as non-adherent. Adherence was not significantly associated with age, gender, nationality, fracture history, polypharmacy, or most comorbidities. In contrast, medication beliefs demonstrated a strong relationship with adherence. In multivariable Firth regression, stronger medication concerns were independently associated with lower odds of adherence (adjusted OR 0.033, 95% CI 0.003 to 0.355; p = 0.0049), while having more than two comorbidities was also associated with reduced adherence (adjusted OR 0.076, 95% CI 0.008 to 0.688; p = 0.022).
Conclusions:
In this UAE real-world cohort, osteoporosis pharmacotherapy was dominated by injectable biologic agents and was prescribed in close agreement with standard dosing recommendations. However, medication adherence remained suboptimal. Patient beliefs, particularly treatment-related concerns, emerged as a more important determinant of adherence than demographic or most clinical characteristics. These findings highlight the need for belief-sensitive, patient-centered adherence interventions alongside optimized pharmacotherapy to improve osteoporosis outcomes in routine practice.
Publication and source details
Original title: Real-World Osteoporosis Pharmacotherapy in the UAE: Prescribing Trends, Adherence, and Patient Beliefs
Maryam Abdulrahman Almoosa Alnuaimi; Syed Arman Rabbani; Khulood Ebrahim Ali Alnaeimi; Khalid Abdulaziz Abu Obaid; Syed Sikandar Shah; Mohamed El-Tanani; Aftab Alam
Healthcare · 2026
* Correspondence: arman@rakmhsu.ac.ae© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:18:27.656767+00:00
DOI: 10.3390/healthcare14091201 · PMC13163328